Trial Profile
Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms GIHP-NACO registry
- 01 Aug 2022 Results (n=478) of an analysis assessing management strategies and outcomes of urgent, non-haemostatic invasive procedures in patients treated with DOACs published in the Thrombosis Research
- 28 Jul 2015 Planned number of patients changed from 300 to 842, as reported by ClinicalTrials.gov.
- 28 Jul 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.